Famotidine

INQUIRY Add to cart

For Research Use Only | Not For Clinical Use

CAT	APS76824356
CAS	76824-35-6
Structure
MDL Number	MFCD00079297
Synonyms	Apo-Famotidine, Famogast,3-[[[2-[(Aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)-propanimidamide, Fibonel, Amfamox, Ganor mite, Famoxal, Restadin, Famox, Fuweidin, Peptifam, Famotin, Gastropen, Pepdif, Quamatel, Fagastine, Famodil, Nulcerin, Antodine, Famocid, Pepcid PM, Ulcetrax, Ulcofam, Pepdine, Pepdul, MK 208, Apogastine, Ulped AR, Motiax, N-(Aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide, Famodine, Famopsin, Purifam, Pepcidin Rapitab, Tamin, Pepfamin, Lecedil, Quamtel, Farmotex, Sedanium R, Ulfagel, Digervin, Kemofam, Peptan, Famonerton, Cepal, Topcid, Famotidine, Nevofam, Famostagine-D, Mosul, Ulfam, Logos, Ulfinol, Fadin, Fenox, Pepcid, Famotal, Durater, Fudone, Fanosin, Pepdul mite, Famodin, Fadine, FamoABZ, Dispronil, Ulped, Gastrion, Muclox, Ifada, Famotep, Pepcidina, Rogasti, Supertidine, Pepcidine, Dispromil, Ulcedine, Gaster, Gastrodomina, Pepcidin, Famo, Famowal, Pepzan, Ulcatif, Ulfamid, Gastridin, Panalba, Facid, Famogard, Fanox, Gastro, Famodar, Ulcidine, Ulceran, YM 11170, Brolin, Ganor, H 2 Bloc, Pepcid AC, Fadyn, Famotine, Weimok, Dibrit 40, 3-[(2-Diaminomethyleneaminothiazol-4-yl)methylthio]-N-sulfamoylpropionamidine, Famos, Agufam, Bestidine, Famosan
IUPAC Name	3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoylpropanimidamide
Molecular Weight	337.45
Molecular Formula	C8H15N7O2S3
Canonical SMILES	NC(=Nc1nc(CSCCC(=NS(=O)(=O)N)N)cs1)N
InChI	InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)
InChI Key	XUFQPHANEAPEMJ-UHFFFAOYSA-N

Accurate Mass	337.0449
Format	Neat

* Products or Services Interested: Famotidine (76824-35-6)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS76824356-1	100MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: British Pharmacopoeia	Inquiry
APS76824356-2	100MG	Room Temperature	+4°C	Subcategory: Pharmaceutical and veterinary compounds and metabolites	Inquiry
APS76824356-3	110MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: European Pharmacopoeia (Ph. Eur.)	Inquiry
APS76824356-4	250MG	Room Temperature	+5°C	API Family: Matrix - API Family Famotidine; Product Type: API; Subcategory: Additional pharmaceutical toxicology reference materials, API standards, Mikromol	Inquiry

Case Study

Famotidine for the Preparation of Silk Fibroin-Chitosan Nanoparticles for Enhanced Gastroprotective Therapy

El-Dakroury, Walaa A., et al. "Famotidine-loaded chitosan hybridized fibroin nanoparticles exhibit outstanding efficacy in ameliorating peptic ulcer." International Journal of Biological Macromolecules (2025): 147321.

Famotidine (FMD), an H₂-receptor antagonist with limited oral bioavailability and a short plasma half-life, was encapsulated within silk fibroin-chitosan nanoparticles (FBN-CS-NPs) to enhance its therapeutic efficacy against peptic ulcers. The study focused on the development, characterization, and in vivo evaluation of this novel nanocarrier system.
1. Nanoparticle Synthesis: Silk fibroin solutions of varying concentrations were prepared in ultrapure water. FMD (20 mg) was dissolved in 99.5% ethanol. The FBN solution (5 mL) was added dropwise to the ethanolic drug solution at a 1:1 volume ratio under constant stirring. The resulting suspension underwent 2 h of stirring to ensure complete nanoparticle formation.
2. Purification and Concentration: Nanoparticles were centrifuged at 16,000 rpm for 2 h, washed twice to remove unbound drug and residual solvents, and finally resuspended in 10 mL distilled water to obtain a concentrated nanoparticle suspension.
3. Characterization: Optimized FMD-FBN-CS-NPs displayed a mean particle size of 94.4 ± 3.6 nm, zeta potential of +65.3 ± 4.6 mV, and 91.5 ± 5.4% drug entrapment efficiency. FTIR and DSC confirmed successful drug incorporation, while TEM indicated a mean nanoparticle size of 81.9 nm. In vitro release studies demonstrated sustained drug release over 24 h.
4. In Vivo Evaluation: In a gastric ulcer rat model, FMD-FBN-CS-NPs enhanced antioxidant defenses (GSH ↑ 436.6%, MDA ↓ 74.19%) and eNOS expression (↑ 466.38%), while significantly reducing H⁺/K⁺ ATPase (↓ 66.67%) and cAMP levels (↓ 77.79%). Histopathology confirmed mucosal healing, and even blank FBN-CS-NPs showed notable gastroprotective effects.
These findings demonstrate that FBN-CS-NPs serve as a dual-function platform, simultaneously improving Famotidine delivery and promoting mucosal protection, establishing a promising strategy for advanced ulcer therapy.

Famotidine for the Therapeutic Application as a GSK-3β Inhibitor in Aluminium Chloride-Induced Alzheimer's Disease

Sequeira, Ronnita C., and Angel Godad. Behavioural Brain Research 476 (2025): 115270.

Famotidine (FMD), a widely used H₂-receptor antagonist, was investigated for its potential neuroprotective role in Alzheimer's disease (AD) via inhibition of glycogen synthase kinase-3β (GSK-3β). This study employed an aluminium chloride (AlCl₃)-induced AD rat model to evaluate famotidine's efficacy in mitigating cognitive deficits, oxidative stress, and amyloid pathology.
1. Experimental Design: AD was induced in rats via oral administration of aluminium chloride hexahydrate (100 mg/kg) once daily for 8 weeks. Famotidine was suspended in 0.5% carboxymethyl cellulose and administered orally at 5, 10, and 20 mg/kg doses from the 5th to the 8th week. Rivastigmine tartrate (1 mg/kg) served as a positive control. Animals were randomly assigned to seven groups (n=8 per group).
2. Behavioral Assessments: Cognitive function was evaluated using Morris Water Maze, Novel Object Recognition, and Y-Maze tests. Famotidine-treated groups exhibited dose-dependent improvements in spatial learning, memory retention, and recognition abilities, comparable to the Rivastigmine group.
3. Biochemical and Molecular Analysis: Famotidine significantly inhibited acetylcholinesterase activity, reduced lipid peroxidation, and enhanced antioxidant defenses. Additionally, famotidine lowered GSK-3β, IL-6, and Aβ(1-42) levels, indicating mitigation of neuroinflammation and amyloid pathology.
4. Histopathology and Molecular Modelling: Histological analysis confirmed preservation of neuronal architecture, while molecular docking suggested efficient binding of famotidine to GSK-3β, supporting its inhibitory potential.
This investigation highlights famotidine as a promising repurposed therapeutic for AD, providing a dual benefit of cognitive improvement and biochemical modulation through GSK-3β inhibition, with the advantage of an established safety profile and oral bioavailability.

Famotidine for the Preparation of Lecithin-Chitosan Nanoparticles for Enhanced Oral Delivery in Gastric Ulcer Therapy

Zewail, Moataz B., et al. Journal of Drug Delivery Science and Technology 91 (2024): 105196.

Famotidine (FMD), a hydrophobic H₂-receptor antagonist with limited oral bioavailability and a short half-life (2.5-4 h), was formulated into lecithin-chitosan nanoparticles (LCNPs) to improve gastric retention, mucoadhesion, and therapeutic efficacy. LCNPs leverage the anionic nature of lecithin and cationic properties of chitosan to encapsulate FMD within a lipophilic core, while the chitosan shell enhances mucosal adherence.
1. Nanoparticle Preparation: FMD (40 mg) was dissolved in 5% ethanolic soy lecithin solution. Chitosan aqueous solutions of varying concentrations (10, 13.33, 20, and 40 mg) were prepared by overnight soaking in 0.2 N HCl at 4 °C and filtered through 0.45 μm membranes. The lecithin-FMD solution (4 mL) was added dropwise to 46 mL of chitosan solution at 1 mL/min under homogenization at 1200 rpm for 30 min. The final suspension pH was adjusted to 4.5 using 0.5 M NaOH.
2. Characterization: The optimized FMD-LCNPs (lecithin:chitosan ratio 10:1) exhibited a particle size of 178.5 ± 9.5 nm, zeta potential of +43.7 ± 2 mV, and an entrapment efficiency of 75.81 ± 2.5 %. Differential scanning calorimetry (DSC), FTIR spectroscopy, and transmission electron microscopy (TEM) confirmed successful drug encapsulation and nanoparticle integrity.
3. In Vitro and In Vivo Performance: LCNPs demonstrated sustained FMD release (75.72 % over 24 h) and strong mucoadhesive properties. In ethanol-induced gastric ulcer rat models, FMD-LCNPs achieved 96.25 % protection, significantly improved antioxidant biomarkers (GSH +162.36 %, MDA -71.91 %), and enhanced eNOS levels (+130.34 %), restoring normal gastric mucosal architecture.
This study establishes famotidine-loaded LCNPs as a promising oral nanocarrier system, offering prolonged release, improved mucosal retention, and superior anti-ulcer efficacy compared to conventional formulations.

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

Name
Phone
* Email
* Quantity
* Products or Services Interested: Famotidine (76824-35-6)
Project Description
* Verification Code

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.

Online Inquiry